ライフサイエンスコーパス: PGJ2

1 oxy-Delta12,14-prostaglandin J2 (dihydro-15d-PGJ2).

2 nd 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2).

3 nd, 15-deoxyDelta12,14-prostagalndin J2 (15D-PGJ2).

4 4) is one of the downstream effectors of 15d-PGJ2.

5 uggesting that KLF4-mediated function of 15d-PGJ2.

6 lls abolished the antifibrotic effect of 15d-PGJ2.

7 uced the protective effects afforded by 15 d-PGJ2.

8 able to block the inhibitory activity of 15d-PGJ2.

9 erived prostaglandins Delta(12)-PGJ2 and 15d-PGJ2.

10 comparable to an intra-TMJ injection of 15d-PGJ2.

11 ma (PPARgamma)-independent cell death by 15d-PGJ2.

12 filaments were altered in cells treated with PGJ2.

13 d apoptotic processes also influenced by 15d-PGJ2.

14 15 d-PGJ2 (0.3 mg/kg intravenously) or vehicle (10% dimethyl

15 rt that the eicosanoid 15-deoxy-Delta(12,14)-PGJ2 (15d-PGJ2) and related cyclopentenone PGs inhibit c

16 ng the endogenous ligand 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2) and synthetic ligands like ciglitazone a

17 the PPAR gamma ligand, 15-deoxy-Delta 12,14-PGJ2 (15d-PGJ2) has been found.

18 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2) has been identified as an endogenous lig

19 ma (PPARgamma), such as 15-deoxy-Delta(12,14)PGJ2 (15d-PGJ2) have been proposed as a new class of ant

20 show that prostaglandin 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2) inactivates CCTalpha by inducing generat

21 or gamma (PPARgamma), such as 15-deoxy-12,14-PGJ2 (15d-PGJ2), have been proposed as a new class of an

22 treatment of monocytes/macrophages with 15d-PGJ2 (2.5 x 10(-6) M) potentiated LPS-induced gene expre

23 PGJ2, a product of cyclooxygenase, is a potent in vitro

24 reduction of C=C by Aor yielding dihydro-15d-PGJ2 abolishes the inducibility in an antioxidant respon

25 Increased production of prostaglandin J2 (PGJ2) activates peroxisome proliferator-activated recept

26 bles, indicating a protective effect of 15 d-PGJ2 against the multiple organ injury/dysfunction cause

27 Physiologically, it is postulated that 15d-PGJ2 alkylates key regulatory proteins via the electroph

28 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2), all inhibited VSMC proliferation and migration.

29 PGJ2 also decreased expression of cell growth/maintenanc

30 Moreover, 15d-PGJ2 also inhibited the LPS/IFN-gamma-induced PI3K-Akt p

31 PGJ2 also perturbed 26 S proteasome assembly and activit

32 Treatment of HUVEC with 15d-PGJ2 also reduced mRNA levels of vascular endothelial ce

33 , treatment of U937 and THP-1 cells with 15d-PGJ2 also resulted in induction of IL-8 gene expression.

34 We show that prostaglandin J2 (PGJ2), an endogenous product of inflammation, disrupts t

35 lasma 15-deoxy-Delta12, 14-prostaglandin J2 (PGJ2, an endogenous PPAR-gamma agonist) levels were also

36 at J-series cyclopentenone PGs, particularly PGJ2 and 15-deoxy-delta12,14-PGJ2, induce proliferation

37 ty, which oxidizes and inactivates Delta(12)-PGJ2 and 15d-PGJ2 In contrast, treatment with the PPARga

38 ed endogenous prostanoids, such as Delta(12)-PGJ2 and 15d-PGJ2, may regulate AAM activation to enhanc

39 studies revealed for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling a

40 looxygenase-derived prostaglandins Delta(12)-PGJ2 and 15d-PGJ2.

41 was also evident at 5 and 10 micromol/L 15d-PGJ2 and 20 micromol/L troglitazone.

42 ance in that two ligands for PPAR gamma, 15d-PGJ2 and a thiazolidinedione, ciglitazone, mediate signi

43 the apoptotic mechanism, the effects of 15d-PGJ2 and ciglitazone on reactive oxygen species were inv

44 This neuroprotective effect of 15d-PGJ2 and ciglitazone was linked to increased PPARgamma D

45 ics methods, we identify 15-deoxy-Delta12,14-PGJ2 and parthenolide as inhibitors of caspase-4-mediate

46 ell as the cyclopentanone prostaglandins 15D-PGJ2 and PGA1) cause a substantial reduction of myocardi

47 r and BALB/c mesangial cells, was blocked by PGJ2 and pioglitazone.

48 cavenger receptor A genes in response to 15d-PGJ2 and synthetic PPAR-gamma ligands.

49 15-d-PGJ2 and troglitazone also blocked NF-kappaB activation

50 Both 15-d-PGJ2 and troglitazone blocked C/EBPbeta transcriptional

51 PPARgamma) in MM cells and its agonists 15-d-PGJ2 and troglitazone completely abolished IL-6-inducibl

52 t resulted in RGC-5 cell death, and both 15d-PGJ2 and troglitazone protected the RGC-5 cells from glu

53 we demonstrate that PPARgamma agonists 15-d-PGJ2 and troglitazone significantly suppress cell-cell a

54 Two PPAR-gamma ligands, 15d-PGJ2 and troglitazone, protect RGC-5, an established tra

55 nflammatory actions of both 15-d-delta 12,14-PGJ2 and troglitazone: 1) the direct inhibition of cytok

56 15-deoxy-delta 12,14 prostaglandin J2 (15-d-PGJ2) and confers cytoprotection against stress stimuli

57 e eicosanoid 15-deoxy-Delta(12,14)-PGJ2 (15d-PGJ2) and related cyclopentenone PGs inhibit caspase-1 a

58 d receptor (PPAR)-gamma and its natural (15d-PGJ2) and synthetic (thiazolidinedione-type) PPAR-gamma

59 ogenous ligand 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2) and synthetic ligands like ciglitazone and troglit

60 lta 12,14-prostaglandin J2 (15-d-delta 12,14-PGJ2) and troglitazone have been examined.

61 sts, 15-deoxy-D(12,14)-prostaglandin J2 (15d-PGJ2) and troglitazone were used.

62 CyPGs), Delta-12 prostaglandin J2 (Delta(12)-PGJ2), and 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ

63 gand, 15d-Delta(12,14)-Prostaglandin J2 (15d-PGJ2), and a selective thiazolidinedione PPARgamma agoni

64 a agonist that is a structural analog of 15d-PGJ2, and lacks the electrophilic carbon of the 15d-PGJ2

65 nd the PGD2 metabolite 15-deoxy-Delta(12,14)-PGJ2, and their divergent roles in immune regulation.

66 15-d-delta 12,14-PGJ2 appears to be approximately 10-fold more effective

67 nti-inflammatory actions of 15-d-delta 12,14-PGJ2 are not limited to peritoneal macrophages, as 15-d-

68 beta, IL-6, and iNOS gene expression) of 15d-PGJ2 are observed to be independent of PPARgamma.

69 and 15-deoxy-Delta(12,14)-prostaglandin J2 (PGJ2) are peroxisome proliferator-activated receptor-gam

70 ctive cyclopentenone prostaglandins PGA2 and PGJ2, are formed non-enzymatically as products of oxidat

71 endent of the well-characterized role of 15d-PGJ2 as a peroxisome proliferator receptor-gamma agonist

72 plementation increases the production of 15d-PGJ2 as an adaptive response to protect cells against ox

73 5-deoxy-(Delta12,14)-prostaglandin J(2) (15d-PGJ2) at 20 micromol/L markedly attenuated the tumor nec

74 gh 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) at micromolar concentrations significantly inhibit

75 Both HGF and 15d-PGJ2 attenuated Smad nuclear translocation in response t

76 The potent PPAR-gamma agonist 15 d-PGJ2 attenuated the increases in the serum concentration

77 Administration of 15d-PGJ2 before and at the onset of clinical signs of EAE si

78 mones, e.g. metabolites of prostaglandin J2 (PGJ2) bind and activate PPARgamma.

79 abolite 15-deoxy-delta prostaglandin J2 (15d-PGJ2) bind to PPAR-gamma and stimulate transcription of

80 ion of PPARgamma by the specific ligands 15d-PGJ2, BRL49653, or ciglitizone, dose dependently suppres

81 4 mRNA expression, 3) KLF4 is induced by 15d-PGJ2 but not by rosiglitazone, a synthetic PPARgamma lig

82 ioxidant, prevented apoptosis induced by 15d-PGJ2, but not by ciglitazone.

83 15d-PGJ2, but not ciglitazone, potently induced reactive oxy

84 nce, exposure of rat cardiac myocytes to 15D-PGJ2, but not to rosiglitazone, results in an up-regulat

85 The secretion of 15-d-PGJ2 by mutant KRAS cells is sufficient to enhance SG fo

86 urrent study addresses the metabolism of 15d-PGJ2 by rat Aor (rAor) and subsequent deactivation of th

87 ectively, these results demonstrate that 15d-PGJ2 can be catabolized by Aor, thereby attenuating subs

88 Here we demonstrate that the 15d-PGJ2 can induce IL-8 gene expression.

89 sodium urate crystals to activate NLRP3, 15d-PGJ2 caused a significant inhibition of cell recruitment

90 In addition, 15d-PGJ2 caused an almost complete depletion of intracellula

91 ic acid (16:0 and 18:1), 15-deoxy-Delta12,14-PGJ2, conjugated LA and azelaoyl-phosphocholine.

92 induction, and neither troglitazone nor 15d-PGJ2 could stimulate the activity of a PPAR-dependent pr

93 15d-PGJ2 cream associated with MNs also significantly reduce

94 Our findings suggest that 15d-PGJ2 cream associated with MNs provides antinociceptive

95 whether the antinociceptive property of 15d-PGJ2 cream can be enhanced with microneedles (MNs).

96 We found that topical application of 15d-PGJ2 cream for 15min directly on the rat TMJ skin did no

97 in the skin for 5min, removed, and then 15d-PGJ2 cream was applied, a significant reduction in forma

98 nd lacks the electrophilic carbon of the 15d-PGJ2 cyclopentenone ring, activated PPARgamma but did no

99 g 15-deoxy-Delta12, 14-prostaglandin J2 (15d-PGJ2) decreased phorbol 12-myristate 13-acetate-induced

100 es of selenium were also mediated by the 15d-PGJ2-dependent activation of the peroxisome proliferator

101 The PGJ2-dependent cytoskeletal rearrangement paralleled the

102 PGJ2 derivatives function as activating ligands for pero

103 15 d-PGJ2 did not affect the biphasic decrease in blood press

104 15d-PGJ2 did not block nuclear translocation or DNA-binding

105 PPARgamma agonist PGJ2 did not enhance insulin-stimulated Na+ flux via ENa

106 imulated BALB/c mesangial cells, supernatant PGJ2 did not increase in MRL/lpr mesangial cell cultures

107 protected against BSO toxicity, whereas 15d-PGJ2 did not.

108 e, and 15-deoxy-Delta12,14-prostaglandin J2 (PGJ2)] do not enhance Na+ transport in cultured renal co

109 The action of 15d-PGJ2 does not appear to involve its nuclear receptor per

110 n of COX-2, production of PGs, including 15d-PGJ2, does not increase during adipocyte differentiation

111 15-Deoxy-Delta12,14-PGJ2 (dPGJ2) is a bioactive metabolite of the J2 series

112 aplantar injection of either H(2)O(2) or 15d-PGJ2 evoked a nocifensive/pain response in wild-type mic

113 glandin 15-deoxydelta-prostaglandin J2 (15 d-PGJ2) exerts potent anti-inflammatory effects in vivo, w

114 Treatment of cells with 8.0 microM 15d-PGJ2 for 24 h caused significant induction of Hsp70 expr

115 in 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) formation, an endogenous inhibitor of IKKbeta acti

116 ibition seen with either troglitazone or 15d-PGJ2, further implicating PPARgamma in these effects.

117 substrate profile, and hMAGL hydrolyzed 15d-PGJ2-G also in living cells.

118 led for the first time that 15d-PGJ2 and 15d-PGJ2-G similarly activated Nrf2 signaling as well as tra

119 The ability of 15d-PGJ2-G to activate the canonical nuclear factor erythroi

120 arly intriguing for MAGL activity toward 15d-PGJ2-G whose hydrolysis rate rivaled that of the best mo

121 elta(12,14)-prostaglandin J2-2-glycerol (15d-PGJ2-G), PGD2-G, PGE2-G, and PGF2 alpha-G.

122 stimulates downstream hBD via a cPLA2a-->15d-PGJ2-->PPARalpha/PPARbeta/delta-->Src kinase-->STAT1/STA

123 In addition, 15-d-PGJ2 had a non-PPARgamma-dependent effect by inactivatio

124 gamma ligand, 15-deoxy-Delta 12,14-PGJ2 (15d-PGJ2) has been found.

125 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2) has been identified as an endogenous ligand for PP

126 mma), such as 15-deoxy-Delta(12,14)PGJ2 (15d-PGJ2) have been proposed as a new class of antiinflammat

127 PPARgamma), such as 15-deoxy-12,14-PGJ2 (15d-PGJ2), have been proposed as a new class of anti-inflamm

128 Not all of the effects of 15D-PGJ2, however, are due to the activation of PPAR-gamma.

129 We demonstrate that PGJ2 impairs 26 S proteasome assembly, which is an ATP-d

130 trometric approaches, we were able to detect PGJ2 in conditioned medium from parental HCA-7 cells.

131 dizes and inactivates Delta(12)-PGJ2 and 15d-PGJ2 In contrast, treatment with the PPARgamma agonist p

132 sponsible for the increased synthesis of 15d-PGJ2 in selenium-supplemented macrophages.

133 observed, with higher concentrations of 15d-PGJ2 in the cream showing a more durable effect up to 8h

134 Culture of encephalitogenic T cells with 15d-PGJ2 in the presence of Ag reduced the ability of these

135 iochemical evidence for the formation of 15d-PGJ2 in vivo is lacking.

136 prostaglandin 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2) inactivates CCTalpha by inducing generation of rea

137 Furthermore, PGJ2 increased the expression of proteasome and other ub

138 s, particularly PGJ2 and 15-deoxy-delta12,14-PGJ2, induce proliferation of these cells at nanomolar c

139 In contrast, PGJ2 induced NAG-1 protein expression, but PGJ2 may not

140 Treatment of mesangial cells with 15d-PGJ2 induced the binding of PPAR-gamma to the peroxisome

141 5-deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ2), induced a novel, nonapoptotic and microtubule-ass

142 y, 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2)-induced Hsp70 was purified from transgenic adenoca

143 othelial cells, which, when treated with 15d-PGJ2, induced receptor translocation into the nucleus, a

144 conferred significant protection against 15d-PGJ2-induced cytoplasmic vacuolation and cell death, sug

145 because a PPARgamma antagonist inhibited the PGJ2-induced expression of NAG-1.

146 Together, these results suggest that 15d-PGJ2-induced growth inhibition of colon cancer cells is

147 ts antagonist (GW9662) did not alter the 15d-PGJ2-induced inhibition of LPS/IFN-gamma-mediated iNOS a

148 We conclude that 15d-PGJ2 induces endothelial cell apoptosis via a PPAR-depen

149 The 15d-PGJ2 inhibited the inflammatory response by inhibiting I

150 Finally, troglitazone and 15d-PGJ2 inhibited the platelet-derived growth factor-BB-ind

151 The 15d-PGJ2 inhibited the recruitment of p300 by NF-kappaB (p65

152 Finally, administration of 15d-PGJ2 inhibited vascular endothelial cell growth factor-i

153 This increase failed to overcome PGJ2 inhibition of 26 S proteasome activity.

154 entration-dependent manner, 15-d-delta 12,14-PGJ2 inhibits each of these proinflammatory actions of L

155 mma ligand 15-deoxy-Delta(12,14)-PGJ(2) (15d-PGJ2) inhibits the proliferation of Ag-specific T cells

156 s studies and by incorporation of biotin-15d-PGJ2 into CCTalpha.

157 ular joint (TMJ) model that injection of 15d-PGJ2 into the rat TMJ can provide antinociceptive relief

158 In this report, we show that 15d-PGJ2 is a potent inducer of caspase-mediated endothelial

159 15d-PGJ2 is detectable as a minor product of COX-2 in human

160 We report that 15d-PGJ2 is detectable using liquid chromatography-mass spec

161 ndent quinone oxidoreductase activity by 15d-PGJ2 is markedly attenuated in mouse embryonic fibroblas

162 15d-PGJ2 is metabolized by recombinant rAor with a Km of 9.6

163 and the inhibitory effect observed with 15d-PGJ2 is most likely mediated by a PPARgamma-independent

164 Furthermore, the biosynthesis of 15d-PGJ2 is not augmented in the joint fluid of patients wit

165 15d-PGJ2 is not the endogenous mediator of PPARgamma-depende

166 Cell death induced by 15d-PGJ2 is prevented by cycloheximide and actinomycin D, su

167 The effect of PGJ2 is probably PPARgamma-dependent because a PPARgamma

168 ne, a synthetic PPARgamma ligand, and 4) 15d-PGJ2 is unable to stimulate PPAR-dependent promoter acti

169 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) is a bioactive prostanoid produced by dehydration

170 15-Deoxy-Delta(12,14) prostaglandin J2 (15d-PGJ2) is a natural ligand for the peroxisome proliferato

171 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) is a reactive membrane lipid metabolite that activ

172 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) is naturally produced in the human body and has an

173 gene expression, we investigated whether 15d-PGJ2 itself affected chemokine gene expression in human

174 ation; and 4) tended to attenuate renal 15-d-PGJ2 levels.

175 15-deoxy-Delta(12,14)-prostaglandin J2 (15-d-PGJ2) levels increased.

176 nisms of the cardioprotective effects of 15D-PGJ2 may include 1) activation of PPAR-alpha, 2) activat

177 ism of suppression of microglial iNOS by 15d-PGJ2 may involve interference with NFkappaB transcriptio

178 , PGJ2 induced NAG-1 protein expression, but PGJ2 may not affect the same region that TGZ does in the

179 neurotoxic products of inflammation, such as PGJ2, may play a role in neurodegenerative disorders ass

180 prostanoids, such as Delta(12)-PGJ2 and 15d-PGJ2, may regulate AAM activation to enhance anti-helmin

181 ering RNA (siRNA) targeting KLF4 reduced 15d-PGJ2-mediated G1 phase arrest, suggesting that KLF4-medi

182 active Akt and PI3K (p110) reversed the 15d-PGJ2-mediated inhibition of p300-induced iNOS and NF-kap

183 Moreover, 15d-PGJ2-mediated KLF4 mRNA expression was blocked by 2'-ami

184 unappreciated function and mechanism of 15d-PGJ2-mediated regulation of cytokine gene expression in

185 15d-PGJ2 modified critical cysteine residues within CCTalpha

186 Furthermore, KLF4 induction by 15d-PGJ2 occurred only in signal transducer and activator of

187 Inhibition by 15D-PGJ2 of the activation of NF-kappaB in turn results in a

188 A direct effect of PGJ2 on actin was not apparent, although actin filaments

189 ntroversy over the inhibitory effects of 15d-PGJ2 on chemokine gene expression, we investigated wheth

190 The effect of 15d-PGJ2 on KLF4 expression seems not to involve its nuclear

191 The inhibitory actions of 15-d-delta 12,14-PGJ2 on LPS + IFN-gamma-induced inflammatory events are

192 Here we investigate the effects of 15 d-PGJ2 on the multiple organ injury/dysfunction associated

193 We previously showed that prostaglandin J2 (PGJ2), one of the endogenous products of inflammation, i

194 not prevent B cell apoptosis induced by 15d-PGJ2 or ciglitazone.

195 We propose that 15 d-PGJ2 or other ligands for PPAR-gamma may be useful in tr

196 e to glutamate exposure, with or without 15d-PGJ2 or troglitazone.

197 ts 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) or troglitazone and ciglitazone suppressed TGF-bet

198 d, 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2), or members of a new class of oral antidiabetic ag

199 However, use of 15d-PGJ2 partially rescued the effects of AMPK activation, s

200 Furthermore, PGJ2 perturbed microtubule polymerization in vitro and d

201 PGJ2 perturbs mitochondrial function, which could be cri

202 pendent cyclopentenone prostaglandin J2 (15d-PGJ2) plays a key role.

203 Instead, 15d-PGJ2 prevents the autoproteolytic activation of caspase-

204 peritoneal macrophages, as 15-d-delta 12,14-PGJ2 prevents TNF-alpha + LPS-induced resident islet mac

205 G) D2-derived cyclopentenone metabolite, 15d-PGJ2, produced by the cyclooxygenase (Ptgs; Cox) pathway

206 We hypothesized that in lupus, a defect in PGJ2 production allows the inflammatory response to cont

207 These studies suggest that abnormalities in PGJ2 production are present in MRL/lpr mice and may be l

208 In contrast to the 2- to 3-fold increase in PGJ2 production by stimulated BALB/c mesangial cells, su

209 s manner and suggest that inhibition of 15-d-PGJ2 production might be a useful therapeutic strategy i

210 s not contain putative PPRE sequence, 2) 15d-PGJ2 rapidly activates extracellular signal-regulated ki

211 15D-PGJ2 reduced the nitration of proteins (immunohistologic

212 The potent PPAR-gamma agonist 15 d-PGJ2 reduces the multiple organ injury and dysfunction,

213 Further studies demonstrated that 15d-PGJ2 regulated IL-8 gene expression via a ligand-specifi

214 cally, modification of protein thiols by 15d-PGJ2 represents a previously undescribed code for redox

215 Treatment of HT-29 cells with 15d-PGJ2 resulted in up-regulation of both KLF4 mRNA and pro

216 re, in a murine anthrax infection model, 15d-PGJ2 reversed anthrax lethal toxin-mediated NLRP1-depend

217 The balance between PGF2 alpha and PGJ2 signaling may thus be central to the development of

218 Transfection studies revealed that 15d-PGJ2 stimulated HGF gene promoter activity, which was de

219 , implicating the reactive nature of the 15d-PGJ2 structure in the apoptosis mechanism.

220 15d-PGJ2 suppressed IFN-gamma, IL-10, and IL-4 production by

221 In activated microglia, 15d-PGJ2 suppressed iNOS promoter activity, iNOS mRNA, and p

222 Although 15d-PGJ2 suppressed PI3-K/AKT and p38 signaling pathways, it

223 This study demonstrates that 15d-PGJ2 suppresses inflammatory response by inhibiting NF-k

224 ize that an altered expression of enzymes in PGJ2 synthesis may represent a novel pathogenic mechanis

225 pose depot-specific expression of enzymes in PGJ2 synthesis, prostaglandin transporter and PPARgamma

226 15-Deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) synthesis.

227 The yield of Hsp70 purified from 15d-PGJ2-treated cells was 4-5-fold higher when compared wit

228 ss-linking, and restored CCT function in 15d-PGJ2-treated cells.

229 Our data support a mechanism by which, upon PGJ2 treatment, cytoskeleton/ER collapse coincides with

230 ptosis, which was further potentiated by 15d-PGJ2 treatment.

231 of human neuroblastoma SK-N-SH revealed that PGJ2 triggered a "repair" response including increased e

232 15-deoxy-Delta(12,14)-prostaglandin J2 (15-d-PGJ2), triggers eIF2alpha phosphorylation, thereby activ

233 s of anti-inflammatory compounds because 15d-PGJ2 was able to inhibit the induction of inflammatory r

234 factor (Nrf2) signaling pathway used by 15d-PGJ2 was assessed, and these studies revealed for the fi

235 This beneficial effect of 15D-PGJ2 was associated with a reduction in the expression o

236 Endothelial apoptosis induced by 15d-PGJ2 was inhibited by treatment of cells with an oligonu

237 A concentration-dependent effect of 15d-PGJ2 was observed, with higher concentrations of 15d-PGJ

238 ependent, as the protection afforded by 15 d-PGJ2 was reduced by the PPAR-gamma antagonist GW9662.

239 15-Deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) was the most potent prostaglandin among those test

240 These effects of 15d-PGJ2 were associated with CCTalpha accumulation within t

241 This was rescued with 15d-PGJ2, which partially recapitulated the effect of seleni

242 tein-1 gene expression was suppressed by 15d-PGJ2, while the expression of RANTES was unaltered.

243 ted with the Michael addition product of 15d-PGJ2 with Cys-179 of IKKbeta, while the formation of suc